These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32666779)

  • 1. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.
    Perdomo C; D'Ingianna P; Escalada J; Petta S; Romero Gómez M; Ampuero J
    Pol Arch Intern Med; 2020 Nov; 130(11):975-985. PubMed ID: 32666779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
    Basu R; Noureddin M; Clark JM
    Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonalcoholic fatty liver disease : Hepatic manifestations of metabolic syndrome].
    Roeb E
    Inn Med (Heidelb); 2023 Apr; 64(4):323-328. PubMed ID: 36580094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.
    Kim KS; Lee BW; Kim YJ; Lee DH; Cha BS; Park CY
    Diabetes Metab J; 2019 Apr; 43(2):127-143. PubMed ID: 30993937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease and non-liver comorbidities.
    Manikat R; Nguyen MH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):s86-s102. PubMed ID: 36603574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
    Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
    Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers.
    Ibrahim MK; Simon TG; Rinella ME
    Clin Liver Dis; 2023 May; 27(2):251-273. PubMed ID: 37024206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.
    Masuoka HC; Chalasani N
    Ann N Y Acad Sci; 2013 Apr; 1281(1):106-22. PubMed ID: 23363012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Hashem A; Khalouf A; Acosta A
    Semin Liver Dis; 2021 Nov; 41(4):435-447. PubMed ID: 34243193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.